Conclusion
neutropenia, breast cancer
NEUTROPENIA, BREAST CANCER
MD‐110 was effective against chemotherapy‐induced neutropenia. No additional safety concern, compared with the originator, was observed in patients with breast cancer receiving TC chemotherapy.(JapicCTI‐205230).Phase III study of MD‐110, a biosimilar of pegfilgrastim, was conducted to investigate the efficacy and safety in early‐stage breast cancer patients receiving neoadjuvant or adjuvant myelosuppressive chemotherapy. MD‐110 was effective against chemotherapy‐induced neutropenia. No additional safety concern, compared with the originator, was observed in patients with breast cancer receiving TC chemotherapy.
